disease 1,782 words KG: ent-dise-420da99b 2026-03-22
kind:diseasesection:diseasesstate:published
Contents

Behavioral Variant Frontotemporal Dementia (bvFTD)

Disease Info
Prevalence15-22 per 100,000 in the 45-65 age group; a 2025 meta-analysis reported a pooled estimate of 9.17 per 100,000[@connectomebased]
Incidence2.7-4.1 per 100,000 person-years
Age at onsetTypically 45-65 years (range 21-85); mean onset age approximately 58 years
SexMale predominance with a ratio of 1.3-1.6:1
Diagnostic delayAverage 3-6 years from symptom onset; approximately 50% receive an initial psychiatric diagnosis[^6]
Proportion of FTDApproximately 60% of all FTD cases
Familial proportionApproximately 40% have a positive family history
Salience networkCentered on the anterior cingulate cortex and frontoinsular cortex; its disruption explains disinhibition, impaired social cognition, and emotional blunting
Default mode networkReciprocal dysregulation with the salience network; paradoxically preserved or increased early in bvFTD
Reward and motivation circuitsVentromedial prefrontal and orbitofrontal cortex dysfunction explains apathy and dietary changes
Theory of mind networkMedial prefrontal and temporal pole disruption underlies loss of empathy
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (16)

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64

Related Analyses (12)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

Related Experiments (16)

Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40